Publications by authors named "Peter W Feit"

Claim this Profile
B
Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Claudia Brandt, Patricia Seja, Kathrin Töllner, Kerstin Römermann, Philip Hampel, Peter W Feit

Neuropharmacology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186-204].
Claudia Brandt, Patricia Seja, Kathrin Töllner, Kerstin Römermann, Philip Hampel, Peter W Feit

Neuropharmacology· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
Kasper Lykke, Kathrin Töllner, Peter W Feit, Thomas Erker, Nanna MacAulay

Epilepsy Behav· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter.
Kasper Lykke, Kathrin Töllner, Kerstin Römermann, Peter W Feit, Thomas Erker

Br J Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.
Kathrin Töllner, Claudia Brandt, Manuel Töpfer, Gerda Brunhofer, Thomas Erker, Peter W Feit

Ann Neurol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis